•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Valneva Reports Five-Year Antibody Persistence for Chikungunya Vaccine
Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®
Valneva Evaluates Next Steps for Bacterial Infection Vaccine Following Successful Phase 2 Studies
Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2
Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Valneva Provides Update on IXCHIQ® in the United Kingdom
Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)
Contrasting Absci (NASDAQ:ABSI) & Valneva (NASDAQ:VALN)
Valneva: The Lyme Royalty Transition Changes The Earnings Model
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
Valneva SE (VALN) Q2 2026 Earnings Call Transcript
Valneva Q2 Earnings Call Highlights
Valneva publie ses résultats financiers du premier semestre 2026 et fait un point sur ses activités
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript
Valneva Announces Successful Outcome of its Annual General Meeting
Already premium?